Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
This article was originally published in The Gray Sheet
Executive Summary
Nestle Health Science will add gastrointestinal diagnostic services to its nutritional health business by acquiring Prometheus Laboratories for undisclosed terms in a deal announced May 24.
You may also be interested in...
Matchmaking And Integration In The New World Of Diagnostics M&A
Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.
A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
With Traditional Chinese Medicine Deal, Nestle’s Health Science Business Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.